Want to see CVRX full AI Analyst Report?
CVRX Stock Chart & Stats
$4.74
$0.14(2.95%)
At close: 4:00 PM EDT
$4.74
$0.14(2.95%)
Day’s Range― - ―
52-Week Range$4.37 - $11.30
Previous Close$4.88
Volume248.25K
Average Volume (3M)197.28K
Market Cap
$142.76M
Enterprise Value$236.42
Total Cash (Recent Filing)$72.30M
Total Debt (Recent Filing)$59.40M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Aug 06, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding26,535,944
10 Day Avg. Volume162,574
30 Day Avg. Volume197,283
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.71
Price to Sales (P/S)3.27
P/FCF Ratio-4.54
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.50Price Target Upside121.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.96
Revenue Forecast (FY)$65.33M
Bulls Say, Bears Say
Bulls Say
High Revenue Growth And Strong Gross MarginsVery strong TTM revenue growth (~427%) combined with an ~86% gross margin indicates robust commercial adoption and attractive unit economics. Durable margin expansion suggests pricing power and manufacturing efficiency, creating a solid foundation for profitability if operating expenses come under control.
Category I CPT Reimbursement MilestoneAchieving a Category I CPT code is a structural reimbursement improvement that reduces billing ambiguity and increases payer acceptance. This change should lower administrative barriers, improve hospital willingness to adopt Barostim, and materially increase revenue visibility and uptake over the medium term.
Expanding Commercial Footprint And Rising ASPGrowth in active implanting centers and sales territories alongside a higher average selling price (~$32K) reflects deeper commercialization and better per-procedure economics. A broader trained provider base and higher ASP support sustainable volume growth and improve revenue per procedure as the therapy scales.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow (TTM OCF ≈ -$39.6M; FCF ≈ -$40.2M) signals ongoing cash burn that will deplete runway absent meaningful cash generation or financing. This pressure forces reliance on capital markets or debt, increasing dilution or financing costs and limiting strategic optionality in the medium term.
Rising Leverage And Compressed EquityLeverage increasing to roughly 2.03x and equity compressing to about $29M materially weaken the balance sheet. Elevated debt raises interest expense and covenant risk, reducing flexibility to fund commercialization or absorb reimbursement setbacks, and heightens the need for external capital under adverse conditions.
High Operating Expenses And Ongoing LossesSustained high operating expense guidance ($103–$107M) and persistent net losses (TTM net margin ≈ -89%, Q1 loss $13.1M) mean the company must achieve substantial scale to reach profitability. Continued heavy investment without faster revenue leverage increases funding needs and extends the timeline to durable profitability.
CVRx News
CVRX FAQ
What was CVRx’s price range in the past 12 months?
CVRx lowest stock price was $4.37 and its highest was $11.30 in the past 12 months.
What is CVRx’s market cap?
CVRx’s market cap is $142.76M.
When is CVRx’s upcoming earnings report date?
CVRx’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were CVRx’s earnings last quarter?
CVRx released its earnings results on May 11, 2026. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.504 by $0.004.
Is CVRx overvalued?
According to Wall Street analysts CVRx’s price is currently Undervalued.
Does CVRx pay dividends?
CVRx does not currently pay dividends.
What is CVRx’s EPS estimate?
CVRx’s EPS estimate is -0.53.
How many shares outstanding does CVRx have?
CVRx has 26,535,944 shares outstanding.
What happened to CVRx’s price movement after its last earnings report?
CVRx reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.504. Following the earnings report the stock price went down -23.844%.
Which hedge fund is a major shareholder of CVRx?
Currently, no hedge funds are holding shares in CVRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CVRx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (121.52% Upside)
$10.50 (121.52% Upside)
Blogger Sentiment
Bullish
CVRX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 207.9K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.04%
Trailing 12-Months
Company Description
CVRx
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
CVRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly constructive operational and commercial picture: strong top-line growth (+20% total, +22% U.S.), margin expansion (87% gross margin), ASP improvement and clear progress on the major clinical trial (BENEFIT-HF) and reimbursement milestones (Category I CPT code). Near-term headwinds are primarily administrative and timing-related (Medicare Advantage prior authorization volatility), plus continued operating losses and elevated operating expense guidance. The positives — revenue acceleration, improving gross margin, clinical trial activation, and reimbursement progress — outweigh the short-term challenges, which management characterizes as addressable and temporary.View all CVRX earnings summariesCVRX Stock 12 Month Forecast
Average Price Target
$10.50
▲(121.52% Upside)
Technical Analysis
Ownership Overview
29.03% Insiders
6.20% Mutual Funds
<0.01% Other Institutional Investors
58.25% Public Companies and
Individual Investors